Lumida
/HIMS
⌘K
Hims & Hers Health Inc

Hims & Hers Health Inc

HIMS
$27.51USD+0.26%+0.07 today

MARKET CAP

6.4B

P/E (TTM)

FWD P/E

DAY RANGE

$27 – $28

52W RANGE

$14
$65

AI Summary

Stalk
TrimMedium

HIMS remains in Stage 3 distribution with a recent support failure confirming medium-term bearish pressure. Price trades below declining 9/20/50 EMAs and the 200-day SMA, and despite being oversold near immediate support, the lack of a clear reversal structure warrants deferring bearish execution. We will trim into rallies around resistance at the 9/20 EMA zone.

  • Q2 revenue $753.2M (+38% YoY) with 300K net subs, totaling ~3M subscribers
  • Raised full-year guidance to $3.1–3.3B on strong subscriber momentum
  • Q2 loss per share $0.37 missed estimates of $0.05; FCF negative $68.2M
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$271.9M$526.9M$872.0M$1.5B$2.3B
YoY %+93.8%+65.5%+69.3%+59.0%
P / Sales4.5x2.5x2.3x3.9x3.6x
EV / Sales4.6x2.5x2.3x3.9x4.2x
Gross Profit, Adj.$204.5M$408.7M$714.9M$1.2B$1.7B
YoY %+99.9%+74.9%+64.1%+47.8%
Margin %75.2%77.6%82.0%79.5%73.8%
EV / Gross Profit6.1x3.2x2.8x4.9x5.6x
EBITDA, Adj.$-111.0M$-61.2M$-19.9M$79.0M$160.1M
YoY %+44.8%+67.4%+496.2%+102.7%
Margin %-40.8%-11.6%-2.3%5.3%6.8%
EV / EBITDA-11.2x-21.2x-101.2x72.6x61.0x
EBIT$-115.0M$-68.7M$-29.5M$61.9M$105.6M
YoY %+40.3%+57.1%+310.2%+70.6%
Margin %-42.3%-13.0%-3.4%4.2%4.5%
EV / EBIT-10.8x-18.9x-68.5x92.7x92.5x
Net Income$-107.7M$-65.7M$-23.5M$126.0M$128.4M
YoY %+39.0%+64.1%+635.3%+1.8%
Net Margin-39.6%-12.5%-2.7%8.5%5.5%
EPS (GAAP)-$0.58-$0.32-$0.11$0.53$0.51
YoY %+44.8%+65.6%+581.8%-3.8%